(Q37055367)

18 August 2017

1 reference

title

The potential of nanoparticle-enhanced imaging (English)

1 reference

18 August 2017

0 references

Adam S Feldman

1

1 reference

18 August 2017

W Scott McDougal

series ordinal

2

1 reference

18 August 2017

Mukesh G Harisinghani

series ordinal

3

1 reference

18 August 2017

language of work or name

1 reference

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

26

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

65-73

1 reference

Nodal staging in genitourinary cancers

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

The frozen section in lymphadenectomy for carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Accuracy of frozen section detection of lymph node metastases in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Open pelvic lymph node dissection for prostate cancer: a reassessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Lymph node size does not correlate with the presence of prostate cancer metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Metastases to pelvic lymph nodes from carcinoma in the pelvic cavity: diagnosis using thin-section CT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

MR evaluation of normal retroperitoneal and pelvic lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Prostatic carcinoma: staging with MR imaging at 1.5 T

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in “high‐risk” prostate cancer compared to MRI or CT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Combined Endorectal and Phased-Array MRI in the Prediction of Pelvic Lymph Node Metastasis in Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Preoperative staging of non-small-cell lung cancer with positron-emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Positron emission tomography in urological oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Positron emission tomography in urologic oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

FDG-PET for preoperative staging of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Evaluation of Neck and Body Metastases to Nodes with Ferumoxtran 10–enhanced MR Imaging: Phase III Safety and Efficacy Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

MR lymphography: study of a high-efficiency lymphotrophic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Axillary lymph node metastases: A statistical analysis of various parameters in MRI with USPIO

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Sensitive, noninvasive detection of lymph node metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

MR lymphangiography for detection of minimal nodal disease in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

MR imaging of mediastinal lymph nodes: evaluation using a superparamagnetic contrast agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Noninvasive detection of clinically occult lymph-node metastases in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Prostate cancer evaluated with ferumoxtran-10-enhanced T2*-weighted MR Imaging at 1.5 and 3.0 T: early experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.016

10.1016/J.UROLONC.2007.03.016

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference